41 results
SGLT2 Inhibitors and Cardiovascular Pathophysiology

#SGLT2i #Inhibitors #Cardiovascular #Pathophysiology
SGLT2 Inhibitors ... Pathophysiology #SGLT2i
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
Clinical Trials of SGLT2 ... ASCVD; signal for SGLT2i ... risk; signal for SGLT2i ... outcomes trial in SGLT2i ... mcclaffertyMD #SGLT2
Algorithm for prescribing SGLT2 inhibitors and GLP1 agonists

This algorithm prioritizes the prescription of SGLT2i and GLP-1
for prescribing SGLT2 ... prescription of SGLT2i ... #SGLT2 #GLP1 #prescribing
Cardiovascular and renal effects comparison between SGLT-2 inhibitors
 - Canagliflozin (Invokana)
 - Dapagliflozin (Farxiga)
 - Empagliflozin
comparison between SGLT ... cardiovascular #renal #SGLT2i
SGLT2 Inhibitors and Euglycemic DKA

Risk factors for euglycemic DKA in those on an SGLT2i include:
 •
SGLT2 Inhibitors ... in those on an SGLT2i ... is closed • SGLT2 ... Kat_Watson #SGLT2
Pathophysiology Euglycemic DKA - Mechanism of SGLT-2 Inhibitors #Pathophys #Endocrine #Euglycemic #DKA #SGLT2 #Mechanism
- Mechanism of SGLT ... Euglycemic #DKA #SGLT2
Pathophysiology of Euglycemic DKA in SGLT2 Inhibitors
 • Kidney: Glycosuria, Natriuresis, ↑ Ketone bodies reabsorption
 •
Euglycemic DKA in SGLT2 ... Euglycemic #DKA #SGLT2i
#SGLT2i #patientinfo #nephrology
#SGLT2i #patientinfo
#diabetes #T2DM #antidiabeticagents #oraldiabeticagents

FIGURE 9.1 Glucose-lowering medication in type 2 diabetes: overall approach. For appropriate context,
receptor agonist; SGLT2i ... , SGLT2 inhibitor
Indications for and pharmacological properties of approved SGLT2 inhibitors

Canagliflozin - Dapagliflozin - Empagliflozin - Ertugliflozin

#SGLT2 #Inhibitors
properties of approved SGLT2 ... Ertugliflozin #SGLT2